Microfragmented Adipose Tissue Injection (MFAT) May Be a Solution to the Rationing of Total Knee Replacement: A Prospective, Gender-Bias Mitigated, Reproducible Analysis at Two Years
Table 8
Patients grouped by BMI at time of treatment (baseline) with follow-up OKS at 3, 6, 12, and 24 months.
Gender
OKS period
Count
Mean
Median
SD
Data
Female
0
43
23.5
23.0
7.3
d1
Female
1
43
31.0
30.0
10.2
d1
Female
2
43
32.0
33.5
10.8
d1
Female
3
43
33.9
33.0
8.7
d1
Female
4
43
33.2
38.5
11.1
d1
Male
0
53
26.9
27.0
10.5
d1
Male
1
53
33.0
34.0
9.3
d1
Male
2
53
32.8
33.0
10.2
d1
Male
3
53
32.5
34.5
11.1
d1
Male
4
53
31.5
30.0
10.5
d1
Female
0
42
25.2
26.5
8.7
d2
Female
1
42
31.9
35.0
10.8
d2
Female
2
42
32.0
35.0
9.6
d2
Female
3
42
32.9
34.0
11.3
d2
Female
4
42
39.4
40.0
5.8
d2
Male
0
67
31.1
32.0
8.0
d2
Male
1
67
34.3
36.0
7.9
d2
Male
2
67
35.4
37.0
7.5
d2
Male
3
67
35.2
36.0
8.7
d2
Male
4
67
35.6
36.5
8.0
d2
Female
0
45
30.7
30.5
8.3
d3
Female
1
45
33.0
33.0
9.3
d3
Female
2
45
34.6
36.0
8.8
d3
Female
3
45
39.0
41.0
6.7
d3
Female
4
45
38.6
37.0
5.4
d3
Male
0
53
32.1
32.0
9.0
d3
Male
1
53
36.5
38.0
8.2
d3
Male
2
53
34.5
34.0
8.7
d3
Male
3
53
37.1
38.0
8.1
d3
Male
4
53
32.6
36.5
12.4
d3
OKS period: 0—baseline, 1—3 months postinjection, 2—6 months postinjection, 3—12 months postinjection, 4—24 months postinjection. Count: the number of patients in each group. Mean, median, and SD (standard deviation). Data: d1—obese (), d2—overweight (), d3—healthy weight ().
